Depolan 10 mg depottabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

depolan 10 mg depottabletter

g.l. pharma gmbh - morphinhydrochloridtrihydrat - depottabletter - 10 mg

Depolan 30 mg depottabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

depolan 30 mg depottabletter

g.l. pharma gmbh - morphinhydrochloridtrihydrat - depottabletter - 30 mg

Depolan 60 mg depottabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

depolan 60 mg depottabletter

g.l. pharma gmbh - morphinhydrochloridtrihydrat - depottabletter - 60 mg

Depolan 100 mg depottabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

depolan 100 mg depottabletter

g.l. pharma gmbh - morphinhydrochloridtrihydrat - depottabletter - 100 mg

Carvykti Den Europæiske Union - dansk - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Adempas Den Europæiske Union - dansk - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hypertension, lunge - antihypertensive midler til pulmonal arteriel hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har været vist i en pah befolkningen, herunder aetiologies af idiopatisk eller arvelige pah eller pah, der er forbundet med bindevævssygdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.